Gemcitabine

specific

A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA. This locks DNA polymerase thereby resulting in "masked termination" during DNA replication. On the other hand, dFdCDP inhibits ribonucl

48

Centers

0

Active Trials

$81M

Cancer Funding

Top Centers for Gemcitabine(48)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
Active Research Program
68.2
2
NCI Clinical
Active Research Program
67.4
3
NCI Comprehensive
Active Research Program
66.7
4
NCI Comprehensive
Active Research Program
66.0
5
NCI Comprehensive
Active Research Program
65.3
6
NCI Comprehensive
Active Research Program
64.5
7
NCI Comprehensive
Active Research Program
63.8
8
NCI Comprehensive
Active Research Program
63.1
9
NCI Comprehensive
Active Research Program
62.3
10
NCI Comprehensive
Active Research Program
61.6
11
NCI Comprehensive
Active Research Program
60.9
12
NCI Comprehensive
Active Research Program
60.2
13
NCI Comprehensive
Active Research Program
59.4
14
NCI Clinical
Active Research Program
58.7
15
NCI Comprehensive
Active Research Program
58.0
16
NCI Comprehensive
Active Research Program
57.2
17
Active Research Program
56.5
18
Active Research Program
55.8
19
NCI Comprehensive
Active Research Program
55.1
20
NCI Comprehensive
Active Research Program
54.3
21
NCI Comprehensive
Active Research Program
53.6
22
NCI Comprehensive
Active Research Program
52.9
2352.1
24
Active Research Program
51.4
2550.7
26
NCI Clinical
Active Research Program
49.9
27
Stephenson Cancer CenterOklahoma City, OK
NCI Clinical
Active Research Program
49.2
28
NCI Comprehensive
Active Research Program
48.5
29
NCI Basic_laboratory
Active Research Program
47.8
30
Active Research Program
47.0
31
Active Research Program
46.3
32
Active Research Program
45.6
33
NCI Comprehensive
39.4
34
NCI Comprehensive
39.4
35
NCI Comprehensive
39.4
3639.4
37
NCI Comprehensive
39.4
3839.4
3939.4
40
Fox Chase Cancer CenterPhiladelphia, PA
NCI Comprehensive
39.4
4139.4
4239.4
4339.4
4439.4
4539.4
4639.4
4739.4
4839.4

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →